Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG
NCT ID: NCT07172620
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
260 participants
OBSERVATIONAL
2025-06-01
2030-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Is the bridge vessel patency rate of patients in the MICS-Notouch group noninferior to that of a saphenous vein bridge with conventional open-chest bypass?
Participants will be divided into two groups:
Exposure group (MICS-Notouch group): non-extracorporeal circulation multiple coronary artery bypass grafting surgery performed under direct visualization of a small incision in the left chest, including the application of LIMA (left internal mammary artery) + SVG (saphenous vein) multiple bypass grafting.
Control group (OPCAB group): conventional median chest opening, non-extracorporeal circulation multi-branch coronary artery bypass graft surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MInithoraCotomy vs Sternotomy for Multivessel Coronary Artery Bypass Grafting: A Partially Randomized Patient Preference Trial Assessing Quality of Life and Patency Outcomes
NCT04795193
The Quality of Life and Patency Rate After Minimally Invasive Cardiac Surgery
NCT05104320
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
NCT03447938
Clinical Effect of No-touch Harvesting Technique in OPCABG
NCT03729531
Prospective Cohort Study on Minimal Invasive Coronary Surgery
NCT04267835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Due to space constraints, MICS-CABG surgery cannot apply a proximal anastomosis to the ascending aorta and requires the use of a special sidewall clamp to clamp the ascending aorta, which poses two potential risks: 1. In patients with calcification and thickening of the ascending aorta, clamping of the ascending aorta may cause rupture of the intimal plaque and dislodgement, which can lead to the risk of cerebral infarction and peripheral arterial embolism; 2. minimal incision In bypass surgery, the proximal anastomosis of the ascending aorta has a very low tolerance rate. Due to the deep location of the ascending aorta, the surgical field and operating space are limited, and the suture is extremely difficult, if the anastomosis process occurs in the case of vascular tear, anastomotic leakage, or dislodgement of the sidewall clamp, it will cause serious uncontrollable aortic bleeding, which may endanger the patient's life in a short period of time.
SIGNIFICANCE: The optimization of the MICS-CABG surgical protocol through this topic reduces the surgical risk and removes the obstacles for the promotion of this technology.
In order to solve the problem of proximal anastomosis of MICS-CABG surgery in patients with calcification of the ascending aorta and to reduce the difficulty and risk of surgery. In 2020, our center began to explore the minimally invasive bypass surgery of ascending aorta non-touch (No-touch) technology, which refers to the bypass surgery without any manipulation of the ascending aorta, the proximal anastomosis of the bridge vessel in the axillary artery, through the first intercostal space of the bridge vessel to the thoracic cavity for the distal continuation of the anastomosis. The advantages of this technique are: 1) avoiding ascending aortic manipulation eliminates the risk of cerebral infarction and peripheral arterial embolism caused by plaque dislodgement from the ascending aorta; 2) the axillary artery rarely exists in calcification, and the vascular condition is good; 3) the axillary artery is simple to reveal, with plenty of room for maneuvering, and it can be anastomosed under direct vision, which greatly reduces the difficulty of the procedure, and if the anastomosis bleeds after the completion of the anastomosis, the bleeding is simple to stop, which decreases the risk of surgical manipulation.
This study will evaluate the safety and efficacy of this technique in a prospective cohort study. If the safety and efficacy of this technique are confirmed to be good, it will greatly expand the indications of this cutting-edge technique of MICS-CABG, optimize the surgical plan, reduce the surgical difficulty and shorten the learning curve.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposure group (MICS-Notouch group)
Patients enrolled underwent non-extracorporeal coronary artery bypass grafting under direct vision through a small left thoracotomy, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein graft) multibranch bypass grafts.
Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.
Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
Control group (OPCAB group)
Patients enrolled underwent conventional median open-heart surgery with multiple coronary artery bypass grafting under off-pump circulation.
Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation
Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-extracorporeal multiple coronary artery bypass graft (CABG) performed under direct visualization through a small incision in the left side of the chest.
Exposure group (MICS-Notouch group): Direct visualization non-extracorporeal coronary artery bypass grafting with a small left chest incision, including the use of LIMA (left internal mammary artery) + SVG (saphenous vein) multibranch bypass grafting.
Multi-branch coronary artery bypass grafting with conventional median open heart and off-pump circulation
Control Group (OPCAB Group): Conventional median open multiple coronary artery bypass grafting with extracorporeal circulation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with calcification of the ascending aorta, as confirmed by CT, who are not suitable for sidewall clamping are also eligible for enrollment.
Exclusion Criteria
* Valve surgery or other intracardiac surgery at the same time;
* Patients expected to undergo extracorporeal circulation surgery;
* Poor myocardial infarction conditions, extensive lesions, distal or full diffuse stenosis, or lumen diameter less than or severe calcification that cannot be anastomosed.
* Previous open heart surgery.
* Patients with preoperative hemodynamic instability requiring emergency surgery.
* Other conditions include terminal malignant tumors, uncontrollable infections, bleeding, persistent progressive degenerative systemic diseases, severe brain injuries, and multiple organ failure. Additionally, other significant organ function serious impairments, such as severe liver function impairment, severe heart failure, or cardiogenic shock, may also be considered contraindications. Inability to tolerate surgery may also be considered a contraindication.
* The participant declines to take part in this study.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ling Yunpeng, PhD
Role: STUDY_CHAIR
Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Arota notouch of MICS-CABG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.